867 Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.35 |
| 52 Week High | HK$15.86 |
| 52 Week Low | HK$6.23 |
| Beta | 0.93 |
| 11 Month Change | -11.55% |
| 3 Month Change | 6.21% |
| 1 Year Change | -47.57% |
| 33 Year Change | -44.57% |
| 5 Year Change | -34.02% |
| Change since IPO | -48.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 867 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -3.4% | 0.07% | -0.6% |
| 1Y | -47.6% | -10.2% | 9.6% |
Return vs Industry: 867 underperformed the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 867 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 867 volatility | |
|---|---|
| 867 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 867 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 867's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,781 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
| 867 fundamental statistics | |
|---|---|
| Market cap | HK$17.76b |
| Earnings (TTM) | HK$1.49b |
| Revenue (TTM) | HK$7.54b |
11.9x
P/E Ratio2.4x
P/S RatioIs 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 867 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.01b |
| Cost of Revenue | CN¥1.85b |
| Gross Profit | CN¥5.17b |
| Other Expenses | CN¥3.78b |
| Earnings | CN¥1.39b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.58 |
| Gross Margin | 73.66% |
| Net Profit Margin | 19.82% |
| Debt/Equity Ratio | 6.9% |
How did 867 perform over the long term?
See historical performance and comparison